Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4259 results
Spotlight Innovation finalizes plans to sign deal with Maitland Labs to establish drug development facility
Spotlight Innovation has finalized plans for entering into an agreement with Maitland Labs, based in Orlando, Florida, to establish its drug production and product development facilities at Maitland Lab’s sterile fill drug production plant, currently under construction.
Drug Research > Drug Discovery & Development > News
Reaction Biology awarded subcontract to help speed up drug discovery
Reaction Biology (RBC) will join a national network of scientists to increase cancer drug discovery and development, centered at the Frederick National Laboratory for Cancer Research.
Drug Research > Drug Discovery & Development > News
FluoroPharma announces letter of intent to buy Ground Fluor Pharmaceuticals
FluoroPharma Medical has entered into a nonbinding letter of intent to acquire Ground Fluor Pharmaceuticals (GFP).
Drug Research > Drug Discovery & Development > News
Merck agrees to buy Afferent Pharmaceuticals in $1.2bn transaction
By PBR Staff Writer
Merck has agreed to acquire clinical-stage biotechnology firm Afferent Pharmaceuticals in a transaction worth about $1.2bn.
Drug Research > Drug Discovery & Development > News
Ultragenyx, Takeda partner to develop rare genetic disease therapies
By PBR Staff Writer
Ultragenyx Pharmaceutical and Takeda Pharmaceutical have partnered to develop and commercialize therapies for rare genetic diseases.
Drug Research > Drug Discovery & Development > News
Pieris Pharmaceuticals closes $16.5m private placement
Pieris Pharmaceuticals announced closing of the private placement consisting of 8,188,804 units at a price of $2.015 per unit, for total gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses.
Drug Research > Drug Discovery & Development > News
Biogen to continue development of opicinumab MS drug despite failure in phase II trial
By PBR Staff Writer
Biogen said it will continue clinical development of opicinumab (anti-LINGO-1) even though the multiple sclerosis (MS) candidate missed its primary endpoint in a phase II trial.
Drug Research > Drug Discovery & Development > News
Adimab, Innovent expand partnership for discovery of antibodies and bispecifics
Adimab and Innovent Biologics announced a significant expansion of their existing collaboration.
Drug Research > Drug Discovery & Development > News
Atossa Genetics starts new drug development program with oral endoxifen
Atossa Genetics has initiated a new drug development program with oral endoxifen.
Drug Research > Drug Discovery & Development > News
EpimAb Biotherapeutics, Innovent Biologics establish multi-target bispecific antibody collaboration
EpimAb Biotherapeutics and Innovent Biologics announced a multiple target agreement for the development of bispecific antibodies.
Drug Research > Drug Discovery & Development > News
Charles River to support Moderna Therapeutics’ nonclinical discovery and development efforts
Moderna Therapeutics and Charles River Laboratories International announced a strategic collaboration to support Moderna’s nonclinical discovery and development efforts.
Drug Research > Drug Discovery & Development > News
ProMIS Neurosciences identifies multiple product candidates targeting Alzheimer’s disease
ProMIS Neurosciences announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer’s disease (AD).
Drug Research > Drug Discovery & Development > News
ChemDiv signs drug discovery collaboration deal with Cystic Fibrosis Foundation Therapeutics
ChemDiv has entered into a new drug discovery collaboration agreement with Cystic Fibrosis Foundation Therapeutics (CFFT).
Drug Research > Drug Discovery & Development > News
Jazz Pharmaceuticals agrees to acquire Celator for $1.5bn
By PBR Staff Writer
Jazz Pharmaceuticals has agreed to acquire oncology-focused biopharmaceutical firm Celator Pharmaceuticals for about $1.5bn.
Drug Research > Drug Discovery & Development > News
Faron expands development strategy for novel immunotherapy drug candidate, Clevegen
Faron Pharmaceuticals has expanded the development strategy for Clevegen, its novel cancer immunotherapy drug candidate.
Drug Research > Drug Discovery & Development > News
61-75 of 4259 results